Literature DB >> 12680148

Bag-1 expression in thyroid neoplasm: its correlation with Bcl-2 expression and carcinoma dedifferentiation.

Yasuhiro Ito1, Hiroshi Yoshida, Keiichi Nakano, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Tamotsu Yokozawa, Fumio Matsuzuka, Nariaki Matsuura, Kennichi Kakudo, Kanji Kuma, Akira Miyauchi.   

Abstract

BACKGROUND: Apoptosis, programmed cell death, is one of the promnent factors in the evaluation of carcinoma characteristics. It is well-known that bcl-2 and its related proteins significantly modulate apoptosis. Bag-1 is a recently identified bcl-2-related protein and is known to be linked to the biological aggressiveness of some carcinomas.
MATERIALS AND METHODS: We immunohistochemically investigated bag-1 and bcl-2 expression in various thyroid neoplasms using monoclonal antibodies.
RESULTS: High bag-1 expression was observed in 66.7% of follicular adenoma and 75.0% of follicular carcinoma, and no statistical difference was established between them. In papillary carcinoma, 60.7% were classified with high bag-1 expression, whereas only 4.5% of anaplastic (undifferentiated) carcinoma highly expressed bag-1, and the incidence was significantly lower (p < 0.0001) than in papillary and follicular carcinomas. Furthermore, in thyroid neoplasm, bag-1 expression was directly linked (p < 0.0001) to bcl-2 expression.
CONCLUSION: These findings suggest that bag-1 may interact with bcl-2 to play an important role in thyroid neoplasm before anaplastic transformation, and the disruption of events mediated by bag-1 and bcl-2 may be a typical characteristic of undifferentiated carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680148

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Correlation between the expression of the BAG-1 gene and clinicopathologic factors in colorectal cancer.

Authors:  Nian-Feng Sun; Qing-Yi Meng; San-Yuan Hu; Ai-Ling Tian; Rui-Hua Wang; Zhao-Xuan Liu; Li Xu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.